A potent and selective inhibitor of endocannabinoid uptake, UCM707, potentiates antinociception induced by cholestasis

Fundamental and Clinical Pharmacology

Volumn 22, Issue 5, 2008, Pages 517-522

  Hasanein, Parisa ^a   Javanmardi, Kazem ^b  

^a BU ALI SINA UNIVERSITY   (Iran)

^b FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antinociception; Cholestasis; Endocannabinoids; Rats; UCM707

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; N (3 FURYLMETHYL)ARACHIDONAMIDE; OPIATE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BILE DUCT LIGATION; CHOLESTASIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; EXPERIMENTAL MODEL; EXTRACELLULAR SPACE; LATENT PERIOD; MALE; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SPRAGUE DAWLEY RAT; TAIL FLICK TEST;

ANIMALS; ARACHIDONIC ACIDS; CHOLESTASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; FURANS; MALE; PAIN; PAIN MEASUREMENT; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 52449114742     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00626.x     Document Type: Article

References (36)

1. Bergasa N.V., Alling D.W., Vergalla J. et al. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J. Hepatol. (1994) 20 85 90.
2. Dehpour A.R., Mani A.R., Amanlou M. et al. Naloxone is protective against indomethacin-induced gastric damage in cholestatic rats. J. Gastroenterol. (1999) 34 178 181.
3. Namiranian K., Samini M., Mehr S.E. et al. Mesenteric vascular bed responsiveness in bile duct-ligated rats: roles of opioid and nitric oxide systems. Eur. J. Pharmacol. (2001) 423 185 193.
4. Dehpour A.R., Sadeghipour H.R., Nowroozi A. et al. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum. Psychopharmacol. (2000) 15 423 428.
5. Thornton J.R., Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ (1988) 297 1501 1504.
6. Bergasa N.V., Rothman R.B., Vergalla J. et al. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J. Hepatol. (1992) 15 220 224.
7. Hasanein P., Parviz M., Keshavarz M. et al. Modulation of cholestasis-induced antinociception in rats by two NMDA receptor antagonists: MK-801 and magnesium sulfate. Eur. J. Pharmacol. (2007) 554 123 127.
8. Rastegar H., Homayoun H., Afifi M. et al. Modulation of cholestasis-induced antinociception by CCK receptor agonists and antagonists. Eur. Europsychopharmacol. (2002) 12 111 118.
9. Di Marzo V., Fontana A., Cadas H. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372 686 691.
10. Hohmann A.G., Suplita R.L. An endocannabinoid mechanism for stress-induced analgesia. AAPS J (2006) 8 E693 708.
11. Giuffrida A., Beltramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. (2001) 298 7 14.
12. Jhaveri M.D., Richardson D., Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. (2007) 152 624 632.
13. Fowler C.J. The cannabinoid system and its pharmacological manipulation-a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam. Clin. Pharmacol. (2006) 20 549 562.
14. López-Rodríguez M.L., Viso A., Ortega-Gutiérrez S. et al. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem. (2001) 44 4505 4508.
15. López-Rodríguez M.L., Viso A., Ortega-Gutiérrez S. et al. Endocannabinoid transporter inhibitors. Curr. Med. Chem. Central Nerv. Syst. Agents (2002) 2 129 141.
16. Corchero J., Manzanares J., Fuentes J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit. Rev. Neurobiol. (2004) 16 159 172.
17. Smith F.L., Fujimori K., Lowe J. et al. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. (1998) 60 183 191.
18. Welch S.P., Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. (1999) 848 183 190.
19. Gingold A.R., Bergasa N.V. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci. (2003) 73 2741 2747.
20. de Lago E., Fernandez-Ruiz J., Ortega-Gutierrez S. et al. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur. J. Pharmacol. (2002) 449 99 103.
21. Javanmardi K., Parviz M., Sadr S.S. et al. Involvement of N-methyl-D-aspartate receptors and nitric oxide in the rostral ventromedial medulla in modulating morphine pain-inhibitory signals from the periaqueductal grey matter in rats. Clin. Exp. Pharmacol. Physiol. (2005) 32 585 589.
22. Swain M.G., Rothman R.B., Xu H. et al. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology (1992) 103 630 635.
23. Swain M.G., MacArthur L., Vergalla J. et al. Adrenal secretion of BAM-22P, a potent opioid peptide, is enhanced in rats with acute cholestasis. Am. J. Physiol. (1994) 266 G201 G205.
24. Thornton J.R., Losowsky M.S. Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J. Hepatol. (1989) 8 53 59.
25. Nelson L., Vergnolle N., D'Mello C. et al. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J. Hepatol. (2006) 44 1141 1149.
26. Costa B., Siniscalco D., Trovato A.E. et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br. J. Pharmacol. (2006) 148 1022 1032.
27. La Rana G., Russo R., Campolongo P. et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404[N-(4-hydroxyphenyl)-eicosa-5, 8, 11, 14-tetraenamide]. J. Pharmacol. Exp. Ther. (2006) 317 1365 1371.
28. Rodella L.F., Borsani E., Rezzani R. et al. AM404, an inhibitor of anandamide reuptake decreases Fosimmunoreactivityin the spinal cord of neuropathic rats after non-noxious stimulation. Eur. J. Pharmacol. (2005) 508 139 146.
29. Herkenham M., Lynn A.B., Little M.D. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA (1990) 87 1932 1936.
30. Matsuda L.A., Lolait S.J., Brownstein M.J. et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346 561 564.
31. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids (2002) 121 173 190.
32. Monhemius R., Azami J., Green D.L. et al. CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res. (2001) 908 67 74.
33. Walker J.M., Huang S.M. Cannabinoid analgesia. Pharmacol. Ther. (2002) 95 127 135.
34. Beltramo M., de Fonseca F.R., Navarro M. et al. Reversal of dopamine D (2) receptor responses by an anandamide transport inhibitor. J. Neurosci. (2000) 20 3401 3407.
35. Fegley D., Kathuria S., Mercier R. et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl Acad. Sci. USA (2004) 101 8756 8761.
36. Beltramo M., Stella N., Calignano A. et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (Wash DC) (1997) 277 1094 1097.